A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Conditions

• Multiple Myeloma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Iberdomide — DRUG
  Specified dose on specified days
• Lenalidomide — DRUG
  Specified dose on specified days

Study Details

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

Key Dates

Start date

Jun 22, 2023

Status verified

Mar 2026

Primary completion

Mar 15, 2029

Completion

Jan 1, 2036

Study Design

Enrollment

1,216 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A1: Iberdomide Dose 1
• Experimental: Arm A2: Iberdomide Dose 2
• Experimental: Arm A3: Iberdomide Dose 3
• Active Comparator: Arm B: Lenalidomide

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: Up to 6 years ]

Central Contacts

• BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  855-907-3286
  [email protected]
• First line of the email MUST contain NCT # and Site #.

Locations (44)

Find similar trials in Aurora, CO

Related Studies

• Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• Family Study of Lymphoproliferative Disorders
  Recruiting · Mayo Clinic · Rochester, Minnesota
• Collection of Samples and Clinical Data From Patients With Amyloid Diseases
  Recruiting · Boston Medical Center · Boston, Massachusetts
• Collection of Tissue Samples for Cancer Research
  Recruiting · National Cancer Institute (NCI) · Sacramento, California